Xvivo Perfusion AB (publ) (LON:0RKL)
London · Delayed Price · Currency is GBP · Price in SEK 176.05
+2.26 (1.30%)
At close: Sep 17, 2025
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of 438.08 million as of September 17, 2025. Its market cap has decreased by -64.82% in one year.
Market Cap
438.08M
Enterprise Value
421.32M
Revenue
63.16M
Ranking
n/a
PE Ratio
51.24
Stock Price
176.05
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 34.98M to 438.08M, an increase of 1,152.38%. That is a compound annual growth rate of 21.55%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 17, 2025 | 438.08M | -60.69% |
| Dec 30, 2024 | 1.11B | 37.94% |
| Dec 29, 2023 | 807.93M | 85.88% |
| Dec 30, 2022 | 434.66M | -35.41% |
| Dec 30, 2021 | 672.92M | -16.86% |
| Dec 30, 2020 | 809.42M | 119.16% |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 176.72B |
| GSK plc | 59.31B |
| Haleon | 30.40B |
| Smith & Nephew | 11.94B |
| ConvaTec Group | 4.76B |
| Hikma Pharmaceuticals | 3.58B |
| HUTCHMED (China) | 2.12B |
| Genus | 1.65B |